久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Tau Therapeutics
研發的T型鈣通道阻滯劑米貝拉地爾（mibefradil）用于實體腫瘤的治療。

Tau Therapeutics is developing oncology drugs for solid tumors that selectively inhibit the T-type calcium channel. The company’s approach, called Interlaced Therapy?, capitalizes on the central role of calcium influx through T-type calcium channels during cancer cell growth. T-type calcium channel blockade with Tau’s drugs arrests tumor cells at their most vulnerable metabolic point in the cell cycle, uniquely amplifying the effects of conventional therapies and overcoming drug resistance.

Tau’s first product, mibefradil, has been used extensively in humans and its safety profile is well known. Mibefradil is now entering clinical trials for brain cancer with support from the NCI.

Tau Therapeutics is a private company based in Charlottesville, VA.